Altimmune (NASDAQ:ALT) Trading Up 7% – Time to Buy?

Shares of Altimmune, Inc. (NASDAQ:ALT) were up 7% during mid-day trading on Wednesday . The stock traded as high as $3.25 and last traded at $3.3050. Approximately 672,482 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 4,310,293 shares. The stock had previously closed at $3.09.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ALT shares. HC Wainwright reaffirmed a “buy” rating on shares of Altimmune in a report on Tuesday, July 28th. Citigroup restated a “market outperform” rating on shares of Altimmune in a research report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Wednesday, June 24th. Citizens Jmp dropped their price objective on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Finally, Leerink Partners assumed coverage on shares of Altimmune in a report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 target price on the stock. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.33.

Altimmune Trading Up 5.0%

The company’s fifty day moving average is $3.00 and its 200-day moving average is $3.21. The company has a market capitalization of $631.21 million, a PE ratio of -4.16 and a beta of 0.18. The company has a debt-to-equity ratio of 0.07, a current ratio of 26.78 and a quick ratio of 26.78.

Altimmune (NASDAQ:ALT) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 31.41%. On average, analysts anticipate that Altimmune, Inc. will post -0.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Altimmune

Hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its holdings in shares of Altimmune by 268.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock valued at $3,221,000 after acquiring an additional 762,223 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Altimmune by 156.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 518,198 shares of the company’s stock worth $1,575,000 after purchasing an additional 316,209 shares during the last quarter. PFG Investments LLC purchased a new position in shares of Altimmune during the first quarter worth $42,000. Beirne Wealth Consulting Services LLC lifted its position in Altimmune by 9.4% during the first quarter. Beirne Wealth Consulting Services LLC now owns 411,858 shares of the company’s stock valued at $1,269,000 after purchasing an additional 35,400 shares during the period. Finally, Rockefeller Capital Management L.P. lifted its position in Altimmune by 79,838.9% during the fourth quarter. Rockefeller Capital Management L.P. now owns 43,167 shares of the company’s stock valued at $156,000 after purchasing an additional 43,113 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.